PCSK9 and familial hypercholesterolemia: Nevertheless, a small-molecule inhibitor of PCSK9 is highly valued as a treatment option for hypercholesterolemia given its capacity to provide a cost-competitive alternative to anti-PCSK9 monoclonal antibodies, coupled with the potential for ease of oral administration (16).